Kirkeby Cell Therapy APS: Financial statements 2023
CVR: 38650165
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Kirkeby Cell Therapy APS (CVR 38650165) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 287,232 and a net result of DKK 234,251 compared with DKK 127,623 the year before. That is an increase of 166.5% compared with the year before. Equity in the 2023 report amounted to DKK 1,706,696. The solvency ratio was 97.2%.
- Gross Profit
- DKK 287,232
- Profit/Loss
- DKK 234,251
- Equity
- DKK 1,706,696
- Total Assets
- DKK 1,756,238
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | 287K | 234K | 1.7M | - |
| 2022 | - | 108K | 128K | 1.6M | - |
| 2021 | - | 247K | 281K | 1.6M | - |
| 2020 | - | 180K | 184K | 1.3M | - |
| 2019 | - | 189K | 256K | 1.1M | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
Kirkeby Cell Therapy APS has published its annual report for 2022. Gross profit came to DKK 107,768, and the net result was DKK 127,623.
About Kirkeby Cell Therapy APS
Kirkeby Cell Therapy APS is a Danish company of the type Anpartsselskab based in Hellerup, founded in 2017. The company is registered under the industry Andre liberale, videnskabelige og tekniske tjenesteydelser i.a.n.. The company was previously named Kirkeby Cell Therapy IVS and Kirkeby Cell Therapey IVS. The management consists of Agnete Kirkeby. The company is owned by Agnete Kirkeby. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK 25,872 and a net result of DKK -19,504 compared with DKK 111,159 the year before. Equity in the 2025 report amounted to DKK 1,541,351.